Longeveron (NASDAQ:LGVN – Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Longeveron to post earnings of ($0.34) per share for the quarter.
Longeveron Trading Down 9.7%
LGVN opened at $1.35 on Monday. The stock has a 50-day moving average price of $1.55 and a 200-day moving average price of $1.72. Longeveron has a 12-month low of $0.77 and a 12-month high of $6.40. The stock has a market capitalization of $20.08 million, a P/E ratio of -0.21 and a beta of 0.38.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Longeveron in a research note on Friday, March 21st.
Longeveron Company Profile
Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.
Recommended Stories
- Five stocks we like better than Longeveron
- 3 Warren Buffett Stocks to Buy Now
- Constellation Powers Up With Reinforced AI Data Center Strategy
- What is the Shanghai Stock Exchange Composite Index?
- Top Analyst-Rated Healthcare Stocks to Watch Now
- How to Invest in the Best Canadian Stocks
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
